Rebecca Mayer Knutsen

Most Recent Articles by Rebecca Mayer Knutsen

Pricing pressure is the new new normal for drugmakers

Pricing pressure is the new new normal for drugmakers

By By

Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.

Top 25 autoimmune brands in 2016, based on U.S. sales

Top 25 autoimmune brands in 2016, based on U.S. sales

By

AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.

MedImmune goes after challenging lupus market

MedImmune goes after challenging lupus market

By

While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.

Drugmakers battle for slice of Humira's billions

Drugmakers battle for slice of Humira's billions

By

Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

By

Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices

More Articles by Rebecca Mayer Knutsen